Determination of rubella virus-specific humoral and cell-mediated immunity in pregnant women with negative or equivocal rubella-specific IgG in routine screening.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
03 2019
Historique:
received: 09 07 2018
revised: 19 01 2019
accepted: 23 01 2019
pubmed: 4 2 2019
medline: 18 2 2020
entrez: 4 2 2019
Statut: ppublish

Résumé

Immunity to rubella-virus (RV) is commonly determined by measuring specific IgG (RV-IgG). However, RV-IgG results may be different and even discordant, depending on the assay used. Cell-mediated immunity is not routinely investigated for diagnostic purposes. Our aim was to investigate humoral and cellular immunity of women with negative or equivocal RV-IgG before, and after post-partum vaccination. A total of 186 pregnant women were included in the study. During pregnancy, humoral immunity was investigated with two RV-IgG immunoassays, an immunoblot and a T-cell mediated immunity test. In the post-partum vaccination period, measuring RV-IgM and RV-IgG avidity allowed us to determine whether women raised a primary or a secondary immune response. Before vaccination, 52.2% women, supposed to be susceptible, had positive anti-E1 RV-IgG indicating strong evidence of previous exposure to RV. All (100%) pregant women who had a positive immunoblot before immunization raised a secondary immune response to vaccination, and 96.8% who had a negative immunoblot before immunization, raised a primary immune response to vaccination. All women who raised a primary immune response after vaccination had negative anti-E1 RV-IgG and negative cell-mediated immunity. These results indicate that individuals can have evidence of protective immunity against rubella despite negative RV-IgG.

Sections du résumé

BACKGROUND
Immunity to rubella-virus (RV) is commonly determined by measuring specific IgG (RV-IgG). However, RV-IgG results may be different and even discordant, depending on the assay used. Cell-mediated immunity is not routinely investigated for diagnostic purposes.
OBJECTIVES
Our aim was to investigate humoral and cellular immunity of women with negative or equivocal RV-IgG before, and after post-partum vaccination.
STUDY DESIGN
A total of 186 pregnant women were included in the study. During pregnancy, humoral immunity was investigated with two RV-IgG immunoassays, an immunoblot and a T-cell mediated immunity test. In the post-partum vaccination period, measuring RV-IgM and RV-IgG avidity allowed us to determine whether women raised a primary or a secondary immune response.
RESULTS
Before vaccination, 52.2% women, supposed to be susceptible, had positive anti-E1 RV-IgG indicating strong evidence of previous exposure to RV. All (100%) pregant women who had a positive immunoblot before immunization raised a secondary immune response to vaccination, and 96.8% who had a negative immunoblot before immunization, raised a primary immune response to vaccination. All women who raised a primary immune response after vaccination had negative anti-E1 RV-IgG and negative cell-mediated immunity.
DISCUSSION
These results indicate that individuals can have evidence of protective immunity against rubella despite negative RV-IgG.

Identifiants

pubmed: 30711798
pii: S1386-6532(19)30020-4
doi: 10.1016/j.jcv.2019.01.009
pii:
doi:

Substances chimiques

Antibodies, Viral 0
rubella antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-33

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

O Picone (O)

Department of Obstetrics and Gynecology, Hôpital Foch, 92120 Suresnes, France; Risk in Pregnancy University Department, IAME, INSERM, Université Paris-Diderot, 75013 Paris, France; Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France.

E Bouthry (E)

Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France; AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804 Villejuif, France.

Y Bejaoui-Olhmann (Y)

AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804 Villejuif, France.

A G Cordier (AG)

Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France; AP-HP, Hôpital Antoine Béclère, Department of Obstetrics, Gynecology and Reproductive Medicine, Univ Paris-Sud, 92140 Clamart, France.

S Nedellec (S)

AP-HP, Hôpital Antoine Béclère, Department of Obstetrics, Gynecology and Reproductive Medicine, Univ Paris-Sud, 92140 Clamart, France.

A Letourneau (A)

AP-HP, Hôpital Antoine Béclère, Department of Obstetrics, Gynecology and Reproductive Medicine, Univ Paris-Sud, 92140 Clamart, France.

M Carbonel (M)

Department of Obstetrics and Gynecology, Hôpital Foch, 92120 Suresnes, France; EA2493, Université Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France.

M Brollo (M)

Hôpital Foch, DRCI-Clinical Research Unit, 92120 Suresnes, France.

L Grangeot-Keros (L)

Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France; AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804 Villejuif, France.

J M Ayoubi (JM)

Department of Obstetrics and Gynecology, Hôpital Foch, 92120 Suresnes, France; EA2493, Université Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France.

A Benachi (A)

AP-HP, Hôpital Antoine Béclère, Department of Obstetrics, Gynecology and Reproductive Medicine, Univ Paris-Sud, 92140 Clamart, France.

E Rouge (E)

Hôpital Foch, DRCI-Clinical Research Unit, 92120 Suresnes, France.

C Vauloup-Fellous (C)

Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France; AP-HP, Hôpital Paul Brousse, Department of Virology, WHO Rubella NRL, 94804 Villejuif, France; Univ Paris-Sud, INSERM U1193, Villejuif, 94804 France. Electronic address: christelle.vauloup@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH